About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 485781, 11 pages
http://dx.doi.org/10.1155/2012/485781
Review Article

Positive and Negative Regulation of Cellular Immune Responses in Physiologic Conditions and Diseases

1Division of Immunology and Allergy, Department of Medicine, Lausanne University Hospital, 1011 Lausanne, Switzerland
2Swiss Vaccine Research Institute, 1011 Lausanne, Switzerland

Received 25 November 2011; Accepted 20 January 2012

Academic Editor: S. Sozzani

Copyright © 2012 S. Viganò et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Chen, “Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity,” Nature Reviews Immunology, vol. 4, no. 5, pp. 336–347, 2004. View at Scopus
  2. C. C. Goodnow, J. Sprent, F. de. S. Groth, and C. G. Vinuesa, “Cellular and genetic mechanisms of self tolerance and autoimmunity,” Nature, vol. 435, no. 7042, pp. 590–597, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Bour-Jordan, J. H. Esensten, M. Martinez-Llordella, et al., “Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family,” Immunological Reviews, vol. 241, no. 1, pp. 180–205, 2011. View at Publisher · View at Google Scholar
  4. B. T. Fife and K. E. Pauken, “The role of the PD-1 pathway in autoimmunity and peripheral tolerance,” Annals of the New York Academy of Sciences, vol. 1217, no. 1, pp. 45–59, 2011. View at Publisher · View at Google Scholar
  5. R. I. Nurieva, X. Liu, and C. Dong, “Molecular mechanisms of T-cell tolerance,” Immunological Reviews, vol. 241, no. 1, pp. 133–144, 2011. View at Publisher · View at Google Scholar
  6. J. M. Curtsinger, D. C. Lins, and M. F. Mescher, “Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function,” Journal of Experimental Medicine, vol. 197, no. 9, pp. 1141–1151, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. T. R. Mempel, S. E. Henrickson, and U. H. Von Andrian, “T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases,” Nature, vol. 427, no. 6970, pp. 154–159, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Curtsinger, C. M. Johnson, and M. F. Mescher, “CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine,” Journal of Immunology, vol. 171, no. 10, pp. 5165–5171, 2003. View at Scopus
  9. P. J. Leibson, “The regulation of lymphocyte activation by inhibitory receptors,” Current Opinion in Immunology, vol. 16, no. 3, pp. 328–336, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Wang, M. Morra, C. Wu et al., “CD150 is a member of a family of genes that encode glycoproteins on the surface of hematopoietic cells,” Immunogenetics, vol. 53, no. 5, pp. 382–394, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. K. S. Boles, S. E. Stepp, M. Bennett, V. Kumar, and P. A. Mathew, “2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes,” Immunological Reviews, vol. 181, pp. 234–249, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Zhu, A. C. Anderson, and V. K. Kuchroo, “TIM-3 and its regulatory role in immune responses,” Current topics in microbiology and immunology, vol. 350, pp. 1–15, 2011. View at Publisher · View at Google Scholar
  13. R. Rodriguez-Manzanet, R. Dekruyff, V. K. Kuchroo, and D. T. Umetsu, “The costimulatory role of TIM molecules,” Immunological Reviews, vol. 229, no. 1, pp. 259–270, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Cai and G. J. Freeman, “The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation,” Immunological Reviews, vol. 229, no. 1, pp. 244–258, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Anumanthan, A. Bensussan, L. Boumsell et al., “Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes,” Journal of Immunology, vol. 161, no. 6, pp. 2780–2790, 1998. View at Scopus
  16. B. Huard, P. Gaulard, F. Faure, T. Hercend, and F. Triebel, “Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand,” Immunogenetics, vol. 39, no. 3, pp. 213–217, 1994. View at Scopus
  17. J. Denoeud and M. Moser, “Role of CD27/CD70 pathway of activation in immunity and tolerance,” Journal of Leukocyte Biology, vol. 89, no. 2, pp. 195–203, 2011. View at Publisher · View at Google Scholar
  18. N. E. Goeken, “Differential stimulatory requirements and regulation of naive and primed human lymphocytes,” Human Immunology, vol. 10, no. 4, pp. 251–263, 1984. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Inaba, J. P. Metlay, M. T. Crowley, and R. M. Steinman, “Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ,” Journal of Experimental Medicine, vol. 172, no. 2, pp. 631–640, 1990. View at Publisher · View at Google Scholar · View at Scopus
  20. S. E. Henrickson, T. R. Mempel, I. B. Mazo et al., “In vivo imaging of T cell priming,” Science Signaling, vol. 1, no. 12, p. pt2, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. S. E. Henrickson, T. R. Mempel, I. B. Mazo et al., “T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation,” Nature Immunology, vol. 9, no. 3, pp. 282–291, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. S. M. Kaech, E. J. Wherry, and R. Ahmed, “Effector and memory T-cell differentiation: implications for vaccine development,” Nature Reviews Immunology, vol. 2, no. 4, pp. 251–262, 2002. View at Scopus
  23. S. M. Kaech and E. J. Wherry, “Heterogeneity and Cell-fate decisions in effector and memory CD8+ t cell differentiation during viral infection,” Immunity, vol. 27, no. 3, pp. 393–405, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. C. R. Mackay, W. L. Marston, and L. Dudler, “Naive and memory T cells show distinct pathways of lymphocyte recirculation,” Journal of Experimental Medicine, vol. 171, no. 3, pp. 801–817, 1990. View at Scopus
  25. V. P. Badovinac and J. T. Harty, “Programming, demarcating, and manipulating CD8+ T-cell memory,” Immunological Reviews, vol. 211, pp. 67–80, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. C. A. Chambers, M. S. Kuhns, J. G. Egen, and J. P. Allison, “CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy,” Annual Review of Immunology, vol. 19, pp. 565–594, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. D. A. Hildeman, Y. Zhu, T. C. Mitchell, J. Kappler, and P. Marrack, “Molecular mechanisms of activated T cell death in vivo,” Current Opinion in Immunology, vol. 14, no. 3, pp. 354–359, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Arnold, D. Brenner, M. Becker, C. R. Frey, and P. H. Krammer, “How T lymphocytes switch between life and death,” European Journal of Immunology, vol. 36, no. 7, pp. 1654–1658, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Chen, A. K. Tai, M. Lin, F. Chang, C. Terhorst, and B. T. Huber, “Increased proliferation of CD8+ T cells in SAP-deficient mice is associated with impaired activation-induced cell death,” European Journal of Immunology, vol. 37, no. 3, pp. 663–674, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. D. L. Mueller, “Mechanisms maintaining peripheral tolerance,” Nature Immunology, vol. 11, no. 1, pp. 21–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. E. A. Butz and M. J. Bevan, “Massive expansion of antigen-specific CD8+ T cells during an acute virus infection,” Immunity, vol. 8, no. 2, pp. 167–175, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Harari, F. B. Enders, C. Cellerai, P. A. Bart, and G. Pantaleo, “Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure,” Journal of Virology, vol. 83, no. 7, pp. 2862–2871, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Harari, V. Dutoit, C. Cellerai, P. A. Bart, R. A. Du Pasquier, and G. Pantaleo, “Functional signatures of protective antiviral T-cell immunity in human virus infections,” Immunological Reviews, vol. 211, pp. 236–254, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Cellerai, M. Perreau, V. Rozot, F. B. Enders, G. Pantaleo, and A. Harari, “Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7Rα (CD127) and perforin expression,” Journal of Virology, vol. 84, no. 8, pp. 3868–3878, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Harari, C. Cellerai, F. B. Enders et al., “Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 41, pp. 16233–16238, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. E. J. Wherry, “T cell exhaustion,” Nature Immunology, vol. 12, no. 6, pp. 492–499, 2011. View at Publisher · View at Google Scholar
  37. M. H. Brown, K. Boles, P. A. Van Der Merwe, V. Kumar, P. A. Mathew, and A. N. Barclay, “2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48,” Journal of Experimental Medicine, vol. 188, no. 11, pp. 2083–2090, 1998. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Latchman, P. F. McKay, and H. Reiser, “Cutting edge: identification of the 2B4 molecule as a counter-receptor for CD48,” Journal of Immunology, vol. 161, no. 11, pp. 5809–5812, 1998. View at Scopus
  39. B. G. Cocks, C. C. J. Chan, J. M. Carballido, H. Yssel, J. E. De Vries, and G. Aversa, “A novel receptor involved in T-cell activation,” Nature, vol. 376, no. 6537, pp. 260–263, 1995. View at Scopus
  40. D. Howie, S. Okamoto, S. Rietdijk et al., “The role of SAP in murine CD150 (SLAM)-mediated T-cell proliferation and interferon γ production,” Blood, vol. 100, no. 8, pp. 2899–2907, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Howie, M. Simarro, J. Sayos, M. Guirado, J. Sancho, and C. Terhorst, “Molecular dissection of the signaling and costimulatory functions of CD150 (SLAM): CD150/SAP binding and CD150-mediated costimulation,” Blood, vol. 99, no. 3, pp. 957–965, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Henning, M. S. Kraft, T. Derfuss et al., “Signaling lymphocytic activation molecule (SLAM) regulates T cellular cytotoxicity,” European Journal of Immunology, vol. 31, no. 9, pp. 2741–2750, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Mehrle, J. Schmidt, M. W. Büchler, C. Watzl, and A. Märten, “Enhancement of anti-tumor activity in vitro and in vivo by CD150 and SAP,” Molecular Immunology, vol. 45, no. 3, pp. 796–804, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. A. G. Castro, T. M. Hauser, B. G. Cocks et al., “Molecular and functional characterization of mouse signaling lymphocytic activation molecule (SLAM): differential expression and responsiveness in Th1 and Th2 cells,” Journal of Immunology, vol. 163, no. 11, pp. 5860–5870, 1999. View at Scopus
  45. S. V. Mikhalap, L. M. Shlapatska, A. G. Berdova, C. L. Law, E. A. Clark, and S. P. Sidorenko, “CDw150 associates with Src-homology 2-containing inositol phosphatase and modulates CD95-mediated apoptosis,” Journal of Immunology, vol. 162, no. 10, pp. 5719–5727, 1999. View at Scopus
  46. N. Nagy, L. Matskova, U. Hellman, G. Klein, and E. Klein, “The apoptosis modulating role of SAP (SLAM associated protein) contributes to the symptomatology of the X linked lymphoproliferative disease,” Cell Cycle, vol. 8, no. 19, pp. 3086–3090, 2009. View at Scopus
  47. G. Henning, M. S. Kraft, T. Derfuss et al., “Signaling lymphocytic activation molecule (SLAM) regulates T cellular cytotoxicity,” European Journal of Immunology, vol. 31, no. 9, pp. 2741–2750, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. M. J. Czar, E. N. Kersh, L. A. Mijares et al., “Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 13, pp. 7449–7454, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. J. L. Cannons, L. J. Yu, B. Hill et al., “SAP regulates TH2 differentiation and PKC-θ-mediated activation of NF-κB1,” Immunity, vol. 21, no. 5, pp. 693–706, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. N. M. Valiante and G. Trinchieri, “Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes,” Journal of Experimental Medicine, vol. 178, no. 4, pp. 1397–1406, 1993. View at Scopus
  51. B. A. Garni-Wagner, A. Purohit, P. A. Mathew, M. Bennett, and V. Kumar, “A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells,” Journal of Immunology, vol. 151, no. 1, pp. 60–70, 1993. View at Scopus
  52. H. Nakajima, M. Cella, H. Langen, A. Friedlein, and M. Colonna, “Activating interactions in human NK cell recognition: the role of 2B4-CD48,” European Journal of Immunology, vol. 29, no. 5, pp. 1676–1683, 1999. View at Publisher · View at Google Scholar · View at Scopus
  53. G. Schuhmachers, K. Ariizumi, P. A. Mathew, M. Bennett, V. Kumar, and A. Takashima, “Activation of murine epidermal γδ T cells through surface 2B4,” European Journal of Immunology, vol. 25, no. 4, pp. 1117–1120, 1995. View at Scopus
  54. S. G. Tangye, H. Cherwinski, L. L. Lanier, and J. H. Phillips, “2B4-mediated activation of human natural killer cells,” Molecular Immunology, vol. 37, no. 9, pp. 493–501, 2000. View at Publisher · View at Google Scholar · View at Scopus
  55. S. R. Ostrowski, H. Ullum, B. K. Pedersen, J. Gerstoft, and T. L. Katzenstein, “2B4 expression on natural killer cells increases in HIV-1 infected patients followed prospectively during highly active antiretroviral therapy,” Clinical and Experimental Immunology, vol. 141, no. 3, pp. 526–533, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Agrawal, J. Marquet, G. J. Freeman et al., “Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells,” Journal of Immunology, vol. 162, no. 3, pp. 1223–1226, 1999. View at Scopus
  57. M. Maeda, C. Carpenito, R. C. Russell et al., “Murine CD160, Ig-like receptor on NK Cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation,” Journal of Immunology, vol. 175, no. 7, pp. 4426–4432, 2005. View at Scopus
  58. K. Tsujimura, Y. Obata, Y. Matsudaira et al., “Characterization of murine CD160+ CD8+ T lymphocytes,” Immunology Letters, vol. 106, no. 1, pp. 48–56, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Buttner, S. Mosig, A. Lechtermann, H. Funke, and F. C. Mooren, “Exercise affects the gene expression profiles of human white blood cells,” Journal of Applied Physiology, vol. 102, no. 1, pp. 26–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. P. Le Bouteiller, J. Tabiasco, B. Polgar, et al., “CD160: a unique activating NK cell receptor,” Immunology Letters, vol. 138, no. 2, pp. 93–96, 2011. View at Publisher · View at Google Scholar
  61. H. Maiza, G. Leca, I. G. Mansur, V. Schiavon, L. Boumsell, and A. Bensussan, “A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity,” Journal of Experimental Medicine, vol. 178, no. 3, pp. 1121–1126, 1993. View at Scopus
  62. J. Rey, J. Giustiniani, F. Mallet et al., “The co-expression of 2B4 (CD244) and CD160 delineates an subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function,” European Journal of Immunology, vol. 36, no. 9, pp. 2359–2366, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Merino, N. Ramírez, C. Moreno, E. Toledo, M. Fernández, and A. Sánchez-Ibarrola, “BY55/CD160 cannot be considered a cytotoxic marker in cytomegalovirus- specific human CD8+ T cells,” Clinical and Experimental Immunology, vol. 149, no. 1, pp. 87–96, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. M. H. Nikolova, M. N. Muhtarova, H. B. Taskov et al., “The CD160+ CD8high cytotoxic T cell subset correlates with response to HAART in HIV-1+ patients,” Cellular Immunology, vol. 237, no. 2, pp. 96–105, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. D. E. Speiser, M. Colonna, M. Ayyoub et al., “The activatory receptor 2B4 is expressed in vivo by human CD8+ effector αβ T cells,” Journal of Immunology, vol. 167, no. 11, pp. 6165–6170, 2001. View at Scopus
  66. L. Monney, C. A. Sabatos, J. L. Gaglia et al., “Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease,” Nature, vol. 415, no. 6871, pp. 536–541, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Hugues, L. Fetler, L. Bonifaz, J. Helft, F. Amblard, and S. Amigorena, “Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity,” Nature Immunology, vol. 5, no. 12, pp. 1235–1242, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. R. C. Taylor, S. P. Cullen, and S. J. Martin, “Apoptosis: controlled demolition at the cellular level,” Nature Reviews Molecular Cell Biology, vol. 9, no. 3, pp. 231–241, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. P. D. Hughes, G. T. Belz, K. A. Fortner, R. C. Budd, A. Strasser, and P. Bouillet, “Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses andprevention of autoimmunity,” Immunity, vol. 28, no. 2, pp. 197–205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. G. Iezzi, K. Karjalainen, and A. Lanzavecchia, “The duration of antigenic stimulation determines the fate of naive and effector T cells,” Immunity, vol. 8, no. 1, pp. 89–95, 1998. View at Publisher · View at Google Scholar · View at Scopus
  71. B. Salomon and J. A. Bluestone, “Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation,” Annual Review of Immunology, vol. 19, pp. 225–252, 2001. View at Publisher · View at Google Scholar · View at Scopus
  72. A. V. Collins, D. W. Brodie, R. J. C. Gilbert et al., “The interaction properties of costimulatory molecules revisited,” Immunity, vol. 17, no. 2, pp. 201–210, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. R. J. Greenwald, G. J. Freeman, and A. H. Sharpe, “The B7 family revisited,” Annual Review of Immunology, vol. 23, pp. 515–548, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Nakae, H. Suto, M. Iikura et al., “Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF,” Journal of Immunology, vol. 176, no. 4, pp. 2238–2248, 2006. View at Scopus
  75. M. Ishida, Y. Iwai, Y. Tanaka et al., “Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues,” Immunology Letters, vol. 84, no. 1, pp. 57–62, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. Y. Latchman, C. R. Wood, T. Chernova et al., “PD-L2 is a second ligand for PD-1 and inhibits T cell activation,” Nature Immunology, vol. 2, no. 3, pp. 261–268, 2001. View at Publisher · View at Google Scholar · View at Scopus
  77. G. J. Freeman, A. J. Long, Y. Iwai et al., “Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation,” Journal of Experimental Medicine, vol. 192, no. 7, pp. 1027–1034, 2000. View at Publisher · View at Google Scholar · View at Scopus
  78. T. Okazaki and T. Honjo, “The PD-1-PD-L pathway in immunological tolerance,” Trends in Immunology, vol. 27, no. 4, pp. 195–201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. H. Nishimura, M. Nose, H. Hiai, N. Minato, and T. Honjo, “Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor,” Immunity, vol. 11, no. 2, pp. 141–151, 1999. View at Publisher · View at Google Scholar · View at Scopus
  80. H. Nishimura, T. Okazaki, Y. Tanaka et al., “Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice,” Science, vol. 291, no. 5502, pp. 319–322, 2001. View at Publisher · View at Google Scholar · View at Scopus
  81. J. R. Sedy, M. Gavrieli, K. G. Potter et al., “B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator,” Nature Immunology, vol. 6, no. 1, pp. 90–98, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. C. Krieg, O. Boyman, Y. X. Fu, and J. Kaye, “B and T lymphocyte attenuator regulates CD8+ T cell-intrinsic homeostasis and memory cell generation,” Nature Immunology, vol. 8, no. 2, pp. 162–171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Cai, A. Anumanthan, J. A. Brown, E. A. Greenfield, B. Zhu, and G. J. Freeman, “CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator,” Nature Immunology, vol. 9, no. 2, pp. 176–185, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. E. J. Wherry, J. N. Blattman, K. Murali-Krishna, R. Van Der Most, and R. Ahmed, “Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment,” Journal of Virology, vol. 77, no. 8, pp. 4911–4927, 2003. View at Publisher · View at Google Scholar · View at Scopus
  85. A. H. Sharpe, E. J. Wherry, R. Ahmed, and G. J. Freeman, “The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection,” Nature Immunology, vol. 8, no. 3, pp. 239–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. A. J. Zajac, J. N. Blattman, K. Murali-Krishna et al., “Viral immune evasion due to persistence of activated T cells without effector function,” Journal of Experimental Medicine, vol. 188, no. 12, pp. 2205–2213, 1998. View at Publisher · View at Google Scholar · View at Scopus
  87. V. Velu, K. Titanji, B. Zhu et al., “Enhancing SIV-specific immunity in vivo by PD-1 blockade,” Nature, vol. 458, no. 7235, pp. 206–210, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. C. L. Day, D. E. Kaufmann, P. Kiepiela et al., “PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression,” Nature, vol. 443, no. 7109, pp. 350–354, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Das, M. Hoare, N. Davies et al., “Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection,” Journal of Experimental Medicine, vol. 205, no. 9, pp. 2111–2124, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Urbani, B. Amadei, D. Tola et al., “PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion,” Journal of Virology, vol. 80, no. 22, pp. 11398–11403, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. N. Nakamoto, H. Cho, A. Shaked et al., “Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade,” PLoS Pathogens, vol. 5, no. 2, Article ID e1000313, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. T. Kozako, M. Yoshimitsu, H. Fujiwara, et al., “PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients,” Leukemia, vol. 23, no. 2, pp. 375–382, 2009. View at Publisher · View at Google Scholar
  93. P. P. Lee, C. Yee, P. A. Savage et al., “Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients,” Nature Medicine, vol. 5, no. 6, pp. 677–685, 1999. View at Publisher · View at Google Scholar · View at Scopus
  94. A. N. Akbar and S. M. Henson, “Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?” Nature Reviews Immunology, vol. 11, no. 4, pp. 289–295, 2011. View at Publisher · View at Google Scholar
  95. Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo, “Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death,” EMBO Journal, vol. 11, no. 11, pp. 3887–3895, 1992. View at Scopus
  96. D. L. Barber, E. J. Wherry, D. Masopust et al., “Restoring function in exhausted CD8 T cells during chronic viral infection,” Nature, vol. 439, no. 7077, pp. 682–687, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. C. Petrovas, J. P. Casazza, J. M. Brenchley et al., “PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection,” Journal of Experimental Medicine, vol. 203, no. 10, pp. 2281–2292, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. A. Harari, C. Cellerai, F. B. Enders et al., “Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 41, pp. 16233–16238, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. L. Trautmann, L. Janbazian, N. Chomont et al., “Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction,” Nature Medicine, vol. 12, no. 10, pp. 1198–1202, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. C. Boni, P. Fisicaro, C. Valdatta et al., “Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection,” Journal of Virology, vol. 81, no. 8, pp. 4215–4225, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. C. Blank, J. Kuball, S. Voelkl et al., “Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro,” International Journal of Cancer, vol. 119, no. 2, pp. 317–327, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. A. J. Gehring, Z. Z. Ho, A. T. Tan et al., “Profile of tumor antigen-specific cd8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma,” Gastroenterology, vol. 137, no. 2, pp. 682–690, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Ahmadzadeh, L. A. Johnson, B. Heemskerk et al., “Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired,” Blood, vol. 114, no. 8, pp. 1537–1544, 2009. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Mumprecht, C. Schürch, J. Schwaller, M. Solenthaler, and A. F. Ochsenbein, “Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression,” Blood, vol. 114, no. 8, pp. 1528–1536, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. L. Zhang, T. F. Gajewski, and J. Kline, “PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model,” Blood, vol. 114, no. 8, pp. 1545–1552, 2009. View at Publisher · View at Google Scholar · View at Scopus
  106. L. Trautmann, L. Janbazian, N. Chomont et al., “Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction,” Nature Medicine, vol. 12, no. 10, pp. 1198–1202, 2006. View at Publisher · View at Google Scholar · View at Scopus
  107. S. D. Blackburn, H. Shin, W. N. Haining et al., “Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection,” Nature Immunology, vol. 10, no. 1, pp. 29–37, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. K. Richter, P. Agnellini, and A. Oxenius, “On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection,” International Immunology, vol. 22, no. 1, pp. 13–23, 2009. View at Publisher · View at Google Scholar
  109. E. J. Wherry, S. J. Ha, S. M. Kaech et al., “Molecular signature of CD8+ T cell exhaustion during chronic viral infection,” Immunity, vol. 27, no. 4, pp. 670–684, 2007. View at Publisher · View at Google Scholar · View at Scopus
  110. R. B. Jones, L. C. Ndhlovu, J. D. Barbour et al., “Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection,” Journal of Experimental Medicine, vol. 205, no. 12, pp. 2763–2779, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. L. Golden-Mason, B. E. Palmer, N. Kassam et al., “Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells,” Journal of Virology, vol. 83, no. 18, pp. 9122–9130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. R. H. McMahan, L. Golden-Mason, M. I. Nishimura et al., “Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity,” Journal of Clinical Investigation, vol. 120, no. 12, pp. 4546–4557, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. B. Vali, R. B. Jones, A. Sakhdari et al., “HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression,” European Journal of Immunology, vol. 40, no. 9, pp. 2493–2505, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. J. Fourcade, Z. Sun, M. Benallaoua et al., “Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients,” Journal of Experimental Medicine, vol. 207, no. 10, pp. 2175–2186, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. K. Sakuishi, L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, and A. C. Anderson, “Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity,” Journal of Experimental Medicine, vol. 207, no. 10, pp. 2187–2194, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. E. Contardi, G. L. Palmisano, P. L. Tazzari et al., “CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction,” International Journal of Cancer, vol. 117, no. 4, pp. 538–550, 2005. View at Publisher · View at Google Scholar · View at Scopus
  117. A. Boasso, M. Vaccari, A. Hryniewicz et al., “Regulatory T-cell markers, indoleamine 2,3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection,” Journal of Virology, vol. 81, no. 21, pp. 11593–11603, 2007. View at Publisher · View at Google Scholar · View at Scopus
  118. D. E. Kaufmann, D. G. Kavanagh, F. Pereyra et al., “Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction,” Nature Immunology, vol. 8, no. 11, pp. 1246–1254, 2007. View at Publisher · View at Google Scholar · View at Scopus
  119. D. E. Kaufmann and B. D. Walker, “PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention,” Journal of Immunology, vol. 182, no. 10, pp. 5891–5897, 2009. View at Publisher · View at Google Scholar · View at Scopus
  120. M. A. Curran, M. Kim, W. Montalvo, A. Al-Shamkhani, and J. P. Allison, “Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production,” PLoS ONE, vol. 6, no. 4, Article ID e19499, 2011. View at Publisher · View at Google Scholar
  121. L. Derre, J. P. Rivals, C. Jandus et al., “BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination,” Journal of Clinical Investigation, vol. 120, no. 1, pp. 157–167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  122. X. S. Xu, Z. Zhang, L. L. Gu, and F. S. Wang, “[BTLA Characterization and its association with disease progression in patients with chronic HIV-1 infection.],” Chinese Journal of Cellular and Molecular Immunology, vol. 25, pp. 1158–1160, 2009.
  123. Z. Zhang, X. Xu, J. Lv, et al., “B and T lymphocyte attenuator down-regulation by HIV-1 depends on type I interferon and contributes to T-cell hyperactivation,” Journal of Infectious Diseases, vol. 203, no. 11, pp. 1668–1678, 2011. View at Publisher · View at Google Scholar
  124. L. R. V. Antonelli, Y. Mahnke, J. N. Hodge et al., “Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome,” Blood, vol. 116, no. 19, pp. 3818–3827, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. J. Matsuzaki, S. Gnjatic, P. Mhawech-Fauceglia et al., “Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 17, pp. 7875–7880, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. D. Peritt, D. A. Sesok-Pizzini, R. Schretzenmair et al., “C1.7 antigen expression on CD8+ T cells is activation dependent: increased proportion of C1.7+CD8+ T cells in HIV-1-infected patients with progressing disease,” Journal of Immunology, vol. 162, no. 12, pp. 7563–7568, 1999. View at Scopus
  127. K. N. Aldy, N. C. Horton, P. A. Mathew, and S. O. Mathew, “2B4+ CD8+ T cells play an inhibitory role against constrained HIV epitopes,” Biochemical and Biophysical Research Communications, vol. 405, no. 3, pp. 503–507, 2011.
  128. H. Williams, K. Macsween, K. McAulay et al., “Analysis of immune activation and clinical events in acute infectious mononucleosis,” Journal of Infectious Diseases, vol. 190, no. 1, pp. 63–71, 2004. View at Publisher · View at Google Scholar · View at Scopus
  129. B. Bengsch, B. Seigel, M. Ruhl, et al., “Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+T cells is linked to antigen recognition and T cell differentiation,” PLoS Pathogens, vol. 6, no. 6, Article ID e1000947, 2010. View at Publisher · View at Google Scholar
  130. B. Raziorrouh, A. Ulsenheimer, W. Schraut, et al., “Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection,” Gastroenterology, vol. 141, no. 4, pp. 1422–1431, 2011. View at Publisher · View at Google Scholar
  131. T. Yamamoto, D. A. Price, J. P. Casazza, et al., “Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection,” Blood, vol. 117, no. 18, pp. 4805–4815, 2011. View at Publisher · View at Google Scholar
  132. A. Kassu, R. A. Marcus, M. B. D'Souza et al., “Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection,” Journal of Immunology, vol. 185, no. 5, pp. 3007–3018, 2010. View at Publisher · View at Google Scholar · View at Scopus
  133. E. J. Lipson and C. G. Drake, “Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma,” Clinical Cancer Research, vol. 17, no. 22, pp. 6958–6962, 2011. View at Publisher · View at Google Scholar
  134. R. Danielli, R. Ridolfi, V. Chiarion-Sileni, et al., “Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy,” Cancer Immunology, Immunotherapy, vol. 61, no. 1, pp. 41–48, 2012. View at Publisher · View at Google Scholar
  135. J. R. Brahmer, C. G. Drake, I. Wollner, et al., “Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates,” Journal of Clinical Oncology, vol. 28, no. 19, pp. 3167–3175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  136. J. Kline and T. F. Gajewski, “Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer,” Current Opinion in Investigational Drugs, vol. 11, no. 12, pp. 1354–1359, 2010.
  137. F. S. Hodi, M. C. Mihm, R. J. Soiffer, et al., “Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 8, pp. 4712–4717, 2003. View at Publisher · View at Google Scholar · View at Scopus
  138. G. Q. Phan, J. C. Yang, R. M. Sherry et al., “Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8372–8377, 2003. View at Publisher · View at Google Scholar · View at Scopus
  139. A. Hryniewicz, A. Boasso, Y. Edghill-Smith et al., “CTLA-4 blockade decreases TGF-β, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques,” Blood, vol. 108, no. 12, pp. 3834–3842, 2006. View at Publisher · View at Google Scholar
  140. V. Cecchinato, E. Tryniszewska, Z. M. Ma et al., “Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection,” Journal of Immunology, vol. 180, no. 8, pp. 5439–5447, 2008. View at Scopus